Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Wolff

Showing results (831-840 of 973) with videos related to

Pageof 98
Sort By:
Oncotarget|February 9, 2013
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trialsIshwaria M Subbiah, Vivek Subbiah, Apostolia M Tsimberidou, et al.
Aging Cell|December 15, 2018
Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adultsAdam R Konopka, Jaime L Laurin, Hayden M Schoenberg, et al.
International Journal of Radiation Oncology, Biology, Physics|October 24, 2006
Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysisPrajnan Das, Edward H Lin, Sumita Bhatia, et al.
Acta Oncologica (Stockholm, Sweden)|January 23, 2015
Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancerAwalpreet S Chadha, Esengul Kocak-Uzel, Prajnan Das, et al.
Pancreas|March 14, 2014
Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumabKatherine Van Loon, Anne M Espinoza, David R Fogelman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2023
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Plos Pathogens|October 21, 2016
Methylfolate Trap Promotes Bacterial Thymineless Death by Sulfa DrugsMarissa B Guzzo, Hoa T Nguyen, Thanh H Pham, et al.
The American Journal of Surgical Pathology|July 23, 2015
Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal AdenocarcinomaLi Liu, Matthew H Katz, Sun M Lee, et al.
Nucleic Acids Research|September 2, 2006
Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockdown miceAngus T De Souza, Xudong Dai, Andrew G Spencer, et al.
Pageof 98

Showing results (831-840 of 973) with videos related to

Sort By:
Pageof 98
Oncotarget|February 9, 2013
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trialsIshwaria M Subbiah, Vivek Subbiah, Apostolia M Tsimberidou, et al.
Aging Cell|December 15, 2018
Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adultsAdam R Konopka, Jaime L Laurin, Hayden M Schoenberg, et al.
International Journal of Radiation Oncology, Biology, Physics|October 24, 2006
Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysisPrajnan Das, Edward H Lin, Sumita Bhatia, et al.
Acta Oncologica (Stockholm, Sweden)|January 23, 2015
Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancerAwalpreet S Chadha, Esengul Kocak-Uzel, Prajnan Das, et al.
Pancreas|March 14, 2014
Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumabKatherine Van Loon, Anne M Espinoza, David R Fogelman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2023
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Plos Pathogens|October 21, 2016
Methylfolate Trap Promotes Bacterial Thymineless Death by Sulfa DrugsMarissa B Guzzo, Hoa T Nguyen, Thanh H Pham, et al.
The American Journal of Surgical Pathology|July 23, 2015
Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal AdenocarcinomaLi Liu, Matthew H Katz, Sun M Lee, et al.
Nucleic Acids Research|September 2, 2006
Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockdown miceAngus T De Souza, Xudong Dai, Andrew G Spencer, et al.
Pageof 98